Research Article
Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism
Table 2
Parameter estimates for each subject who underwent pharmacokinetic testing at 1, 2, 4, and 8 hours.
| ID |
(ng/mL) | (h) | AUCT (ng/mL) |
| 1 | 23.35 | 1 | 112.35 | 2 | 52.06 | 2 | 167.36 | 3 | 54.41 | 1 | 179.19 | 4 | 57.74 | 1 | 219.72 | 5 | 153.57 | 1 | 327.54 | 6 | 60.64 | 2 | 281.29 | 7 | 19.46 | 1 | 59.39 |
| Mean | 60.18 | 1.29 | 192.41 | SD | 44.43 | 0.49 | 92.93 |
|
|